Roxane Laboratories, a US-based subsidiary of Germany's Boehringer Ingelheim, oversees the development, manufacturing, and marketing of its parent company's multisource (generic) drugmaking business in the US. It sells about 75 medications in 250 package sizes, focusing on oral liquids, sustained-release and controlled-release tablets, cancer drugs, and nasal sprays. It also distributes narcotics, such as meperidine (generic Demerol) and methadone. Products developed and marketed by Roxane are manufactured by its sister company, Boehringer Inghelheim Roxane, also located in Columbus, Ohio.

Founded in 1981, Generics (UK) Limited is a subsidiary of Mylan, the world's third largest generic drug maker. Generics (UK) Limited covers the pharmaceutical business. The name pretty much says it all. Generics (UK) Limited is one of the UK's largest generic pharmaceutical manufacturers, offering a line of more than 350 products sold to pharmacy retailers, hospitals, and wholesale customers. The company makes generic equivalents of such drugs as acid reflux remedy Pepcid, antibiotic Cipro, and allergy treatment Zyrtec.

AMAG Pharmaceuticals, Inc. company was founded in 1981 and is based in Lexington, Massachusetts. AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic iron compounds to treat anemia in the United States, Europe, and Japan. It also provides novel imaging agents to aid in the diagnosis of cancer and cardiovascular diseases. It offers Feraheme, an iron replacement therapeutic agent for the treatment of iron deficiency anemia and used as a diagnostic agent for vascular enhanced magnetic resonance imaging (MRI) to assess peripheral arterial disease; and GastroMARK used for delineating the bowel in MRI. AMAG Pharmaceuticals products also include Combidex, an investigational functional molecular imaging agent.

TopoTarget A/S company develops and markets anti-cancer drugs, as well as therapies for cancer-related conditions. Its portfolio includes preclinical candidates, drugs in clinical development, and marketed products. Its Savene therapy is sold in Europe and is a detoxifying drug which limits tissue damage after accidental exposure to certain chemotherapy agents; the drug is also marketed as Totect in the US. Founded in 2000, TopoTarget works with academic and commercial development partners in the US and Europe. Its biopharmaceutical candidates aim to fight cancers such as lymphoma, melanoma, and ovarian, breast, and neck cancers.

Aaron Industries makes a lot of products you might be familiar with, but under different names. The pharmaceutical company makes approximately 75 different branded and private-label generic products, including alcohol, hydrogen peroxide, mouthwash, hair gel, and antacids and laxatives. It also produces cold medicine and cough suppressants and personal care products such as body sprays and lotions, as well as food-grade chemicals. Brands include Tussin, Pharmacist Preference, and Peptic Relief. Aaron Industries provides contract manufacturing and logistics services. The company operates two manufacturing facilities, one in California and one in South Carolina.

SciClone Pharmaceuticals, Inc. company was founded in 1989 and is headquartered in Foster City, California. SciClone Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cancer and infectious diseases in China and internationally. It provides ZADAXIN for the treatment of hepatitis B and hepatitis C, and certain cancers, as well as for use as a vaccine adjuvant. SciClone's products under development includes ZADAXIN, a thymalfasin, which is in Phase III clinical trials for the treatment of stage IV melanoma; RP101, which is in Phase II clinical trials for the treatment of pancreatic cancer; and SCV-07, which is in Phase II clinical trials for the treatment of hepatitis C virus and oral mucositis. It also holds Chinese marketing rights from Biocompatibles International plc. for DC Bead, a product for the treatment of liver cancer or hepatocellular carcinoma.

Intarcia Therapeutics (formerly BioMedicines) sniffs out the competition for its drugs. The development-stage company identifies potential drug candidates in other firms' pipelines, then buys the rights to products it believes can be developed more efficiently or can be effective in treating different indications. Lead drug candidate Atamestane, acquired from Schering AG (now Bayer Schering ), is in clinical trials as a potential treatment for metastatic breast cancer. The company's pipeline also includes omega interferon (purchased from Boehringer Ingelheim), which is being developed to treat hepatitis C; and Biomed 101 (from G.D. Searle), which may have applications for melanoma and kidney cancer.

Alfacell Corporation was founded in 1981 and is headquartered in Somerset, New Jersey. Alfacell Corporation, a biopharmaceutical company, primarily engages in the discovery and development of a class of therapeutic drugs for the treatment of cancer and other pathological conditions. Its proprietary drug discovery and development program consists of therapeutics developed from amphibian ribonucleases. The company's lead drug product candidate, ONCONASE is evaluated in human clinical trials for the treatment of various forms of cancer. It also focuses on new drug application for unresectable malignant mesothelioma. In addition, the company completed a Phase I clinical trial for the treatment of non-small cell lung cancer.

Labopharm Inc., a specialty pharmaceutical company, develops drugs by incorporating its proprietary controlled-release technologies. It offers once-daily formulation of the analgesic tramadol under the RYZOLT brand name for the treatment of severe chronic pain in adults. The company sells RYZOLT primarily in the United States, Europe, Canada, South Korea, and Australia. Labopharm's products in pipeline include once-daily formulation of trazodone, a serotonin antagonist reuptake inhibitor for the treatment of depressive disorder. Its product candidates in clinical development based on Contramid platform comprise twice-daily formulation of tramadol plus acetaminophen to address acute pain; and Abuse Deterrent Platform to provide safer medications through resistance to the uncontrolled release of the active ingredient after actions, such as breaking, chewing, crushing and heating, or consumption with alcohol. Its product candidates in clinical development based on the Polymeric Nano-Delivery System platform comprise lipid-and preservative-free formulation of the intravenous anaesthetic agent propofol; and SN-38, which is the active metabolite in the prescribed intravenous colon cancer drug irinotecan.

Alexza Pharmaceuticals, Inc. was founded in 2000 and is based in Mountain View, California. Alexza Pharmaceuticals, Inc., a specialty pharmaceutical development stage company, focuses on the research, development, and commercialization of products for the acute treatment of central nervous system conditions. Its technology, Staccato system, vaporizes an excipient-free drug to form a condensation aerosol that allows for systemic drug delivery. The company has six product candidates in clinical development, including AZ-004 (Staccato loxapine) that completed Phase 3 clinical trial for the acute treatment of agitation in patients with schizophrenia or bipolar disorder; AZ-104 (Staccato loxapine), which completed Phase 2a clinical trial to treat patients suffering from acute migraine headaches; and AZ-001 (Staccato prochlorperazine) that completed Phase 2b clinical trials to treat patients suffering from acute migraine headaches.Alexza products in clinical development also include AZ-007 (Staccato zaleplon), which completed Phase 1 clinical trial for the treatment of insomnia in patients who have difficulty falling asleep, including patients who awake in the middle of the night and have difficulty falling back asleep; AZ-003 that completed Phase 1 clinical trial (Staccato fentanyl) for the treatment of patients with acute pain, including patients with breakthrough cancer pain and postoperative patients with acute pain episodes; and AZ-002 (Staccato alprazolam), which completed Phase 2a proof-of-concept clinical trial for the treatment of panic attacks. The company has a development agreement with Autoliv ASP, Inc. to develop heat packages to incorporate into the company's single dose drug delivery devices. It was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.